[HTML][HTML] Ischemic cardiomyopathy and heart failure after acute myocardial infarction

MG Del Buono, F Moroni, RA Montone… - Current Cardiology …, 2022 - Springer
Abstract Purpose of Review Ischemic cardiomyopathy refers to systolic left ventricular
dysfunction in the setting of obstructive coronary artery disease and represents the most …

[HTML][HTML] Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?

J Carberry, G Marquis-Gravel, E O'Meara… - JACC: Heart Failure, 2024 - Elsevier
As a result of the widespread use of reperfusion therapies and secondary prevention over
the last 30 years, there has been a dramatic reduction in the risk of mortality and …

Heart failure after ST-elevation myocardial infarction: beyond left ventricular adverse remodeling

MG Del Buono, CM Garmendia, IM Seropian… - Current problems in …, 2023 - Elsevier
ST-segment elevation myocardial infarction (STEMI) remains a significant source of
morbidity and mortality worldwide. Despite advances in treatment leading to a significant …

Treatment of asymptomatic left ventricular dysfunction

GV Moukarbel, SD Solomon - Current treatment options in cardiovascular …, 2008 - Springer
Opinion statement Patients with abnormalities of left ventricular (LV) systolic or diastolic
function may have no symptoms, especially in the early stages. These patients are not …

New and emerging pharmacological strategies in the management of chronic heart failure

H Krum - Current opinion in Pharmacology, 2001 - Elsevier
Chronic heart failure is a complex syndrome involving the activation of multiple cellular,
metabolic and neurohumoral pathways following the initial myocardial insult. Because of the …

Long-term pharmacological management of reduced ejection fraction following acute myocardial infarction: Current status and future prospects

AAI Abel, AL Clark - International Journal of General Medicine, 2021 - Taylor & Francis
Heart failure (HF) with reduced ejection fraction is common following acute myocardial
infarction (MI), and active medical management can have a profound impact on prognosis …

PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction

G Liuzzo, M Volpe - 2022 - academic.oup.com
• The industry-sponsored, international, multicenter, randomized, double-blind, active-
comparator trial, PARADISE-MI 1 (Prospective ARNI vs. ACE Inhibitor Trial to Determine …

Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction: a review

J Harrington, MC Petrie, SD Anker, DL Bhatt… - JAMA …, 2022 - jamanetwork.com
Importance Despite advances in cardiac care, patients remain at a high risk of death and the
development of heart failure (HF) following myocardial infarction (MI). These risks are …

[引用][C] LV dysfunction and heart failure following myocardial infarction

RD Patten, JE Udelson, MA Konstam - Heart Failure Management, 2000

Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure

J Tamargo, J López-Sendón - Revista Española de Cardiología (English …, 2004 - Elsevier
Congestive heart failure is a leading cause of cardiovascular morbidity and mortality, and is
the main cause of hospitalization among patients older than 65 years. Moreover, its …